When the data for the 14 bipolar II patients were examined
separately, there was a significant improvement
in MADRS scores over the course of treatment (F =7.39;
df = 3, 11; p = 0.006). Improvement from baseline was
significant at week 2 and week 4, but not at week 8,
with a reduction of −5.07 on the MADRS from baseline
(p = 0.058). CGI-S was similarly significantly improved
from baseline to weeks 2 and 4, but not week 8. There
was no significant improvement for YMRS at any of the
time points. Response and remission rates were slightly
lower in the bipolar II group only.
8 weeks were classified as both responders and remitters.